Innovation Pharmaceuticals Inc. (IPIX)
OTCMKTS · Delayed Price · Currency is USD
0.0006
0.00 (0.00%)
At close: Jul 29, 2026
IPIX Balance Sheet
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
Assets
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Sep '23 Sep 30, 2023 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | Jun '19 Jun 30, 2019 |
Cash & Equivalents | 0.86 | 1.52 | 3.81 | 10.19 | 6.02 | 0.58 |
Cash & Short-Term Investments | 0.86 | 1.52 | 3.81 | 10.19 | 6.02 | 0.58 |
Cash Growth | -70.89% | -60.13% | -62.66% | 69.39% | 939.38% | -76.11% |
Prepaid Expenses | 0.08 | 0.12 | 0.15 | 0.5 | 0.09 | 0.05 |
Total Current Assets | 0.94 | 1.63 | 3.95 | 10.69 | 6.11 | 0.63 |
Property, Plant & Equipment | - | - | - | - | - | 0 |
Long-Term Investments | 3.74 | 3.81 | 3.98 | - | - | - |
Other Intangible Assets | 1.91 | 2 | 2.31 | 2.75 | 3.06 | 3.34 |
Long-Term Deferred Charges | - | - | 0.06 | 0.78 | - | - |
Other Long-Term Assets | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 |
Total Assets | 6.67 | 7.52 | 10.38 | 14.3 | 9.25 | 4.05 |
Liabilities
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Sep '23 Sep 30, 2023 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | Jun '19 Jun 30, 2019 |
Accounts Payable | 3.02 | 1.5 | 1.08 | 1.08 | 0.56 | 0.64 |
Accrued Expenses | 1.78 | 1.76 | 1.73 | 2.34 | 3.27 | 3.25 |
Short-Term Debt | 0.24 | 0.21 | 0.25 | 1.46 | 1.9 | 1.92 |
Current Portion of Leases | - | 0.06 | 0.2 | 0.17 | 0.14 | - |
Other Current Liabilities | 0.01 | 1.49 | 1.55 | 1.5 | 1.5 | 1.49 |
Total Current Liabilities | 5.05 | 5.02 | 4.81 | 6.54 | 7.37 | 7.3 |
Long-Term Debt | 0.46 | 0.46 | 0.79 | - | - | 0.88 |
Long-Term Leases | - | - | 0.06 | 0.25 | 0.42 | - |
Total Liabilities | 5.51 | 5.48 | 5.65 | 6.79 | 7.79 | 8.18 |
Shareholders' Equity
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Sep '23 Sep 30, 2023 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | Jun '19 Jun 30, 2019 |
Common Stock | 0.05 | 0.05 | 0.05 | 0.04 | 0.03 | 0.02 |
Additional Paid-In Capital | 129.57 | 129.57 | 129.09 | 124.84 | 102.82 | 90.54 |
Retained Earnings | -126.21 | -125.33 | -122.16 | -115.12 | -101.24 | -94.6 |
Treasury Stock | -2.25 | -2.25 | -2.25 | -2.25 | -0.15 | -0.09 |
Shareholders' Equity | 1.16 | 2.04 | 4.73 | 7.51 | 1.46 | -4.13 |
Total Liabilities & Equity | 6.67 | 7.52 | 10.38 | 14.3 | 9.25 | 4.05 |
Additional Metrics
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Sep '23 Sep 30, 2023 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | Jun '19 Jun 30, 2019 |
Total Debt | 0.7 | 0.73 | 1.29 | 1.87 | 2.46 | 2.8 |
Net Cash (Debt) | 0.17 | 0.79 | 2.52 | 8.32 | 3.56 | -2.22 |
Net Cash Growth | -90.24% | -68.52% | -69.73% | 133.63% | - | - |
Net Cash Per Share | 0.00 | 0.00 | 0.01 | 0.02 | 0.01 | -0.01 |
Filing Date Shares Outstanding | 518.35 | 518.35 | 503.87 | 452.74 | 347.19 | 212.5 |
Total Common Shares Outstanding | 518.35 | 518.35 | 503.87 | 433.8 | 330.99 | 203.31 |
Working Capital | -4.11 | -3.39 | -0.86 | 4.15 | -1.26 | -6.67 |
Book Value Per Share | 0.00 | 0.00 | 0.01 | 0.02 | 0.00 | -0.02 |
Tangible Book Value | -0.75 | 0.04 | 2.42 | 4.76 | -1.6 | -7.47 |
Tangible Book Value Per Share | -0.00 | 0.00 | 0.00 | 0.01 | -0.00 | -0.04 |